At AAM, we take seriously our remit as a membership organization. And as AAM CEO, I feel strongly about the importance of putting membership front and center – being oriented toward representing a greater percentage of the industry, providing value to those who belong and engaging our members on behalf of our mission.
Having more generic and biosimilar manufacturing leaders bringing a variety of experience to – and building consensus on – issues critical to patients and the industry creates a formidable force for positive change. Our ability to champion a brighter, bolder, more sustainable future is greatly enhanced when we speak with one voice on Capitol Hill, in the states, at the FDA and with the Administration.
To ensure we have as many generic and biosimilar companies as possible represented and engaged at AAM, I have made organizational changes to underscore our commitment to membership recruitment and service. Jewel Smith has been promoted to Vice President, Membership and Operations. She will be supported by Maria Pacheco, who has been promoted to Director, Executive Office, Board and Member Relations. These are the first two AAM staff to have “Member” in their titles. This is long overdue, and just the start.
AAM members are united by the association’s mission to provide more patients with the safe and effective generic and biosimilar medicines they need when they need them. I look forward to working with Jewel and Maria and the rest of our association team to strengthen our commitment to our mission by strengthening our commitment to our members.
By Dan Leonard, AAM President and CEO
Published on September 30, 2021